CytomX Therapeutics, Inc. 4
4 · CytomX Therapeutics, Inc. · Filed Aug 11, 2016
Insider Transaction Report
Form 4
GLUCK FREDERICK W
Director
Transactions
- Exercise/Conversion
Common Stock
2016-08-09$1.45/sh+27,606$39,998→ 223,776 total - Exercise/Conversion
Stock Option (right to buy)
2016-08-09−16,612→ 0 totalExercise: $0.94Exp: 2023-02-25→ Common Stock (16,612 underlying) - Exercise/Conversion
Stock Option (right to buy)
2016-08-09−17,139→ 0 totalExercise: $1.57Exp: 2025-02-08→ Common Stock (17,139 underlying) - Exercise/Conversion
Common Stock
2016-08-09$0.94/sh+16,612$15,698→ 196,170 total - Exercise/Conversion
Common Stock
2016-08-09$1.57/sh+17,139$26,992→ 240,915 total - Exercise/Conversion
Stock Option (right to buy)
2016-08-09−31,767→ 0 totalExercise: $1.13Exp: 2021-03-23→ Common Stock (31,767 underlying) - Exercise/Conversion
Stock Option (right to buy)
2016-08-09−27,606→ 0 totalExercise: $1.45Exp: 2024-05-23→ Common Stock (27,606 underlying) - Exercise/Conversion
Common Stock
2016-08-09$1.13/sh+31,767$36,021→ 179,558 total
Holdings
- 331,643(indirect: By Trust)
Common Stock
- 3,200(indirect: By Spouse)
Common Stock
- 22,111(indirect: By LLC)
Common Stock
Footnotes (3)
- [F1]The Reporting Person is a trustee of Frederick W. Gluck 1997 Family Trust dtd July 28, 1997.
- [F2]Richlin Partners, LLC is an entity owned of record by the spouse of the Reporting Person.
- [F3]100% of the shares subject to the option are fully vested and exercisable.